Advertisement

Topics

AstraZeneca sells drug rights for $815 million

11:43 EDT 30 Oct 2018 | Pharmaceutical Manfacturing

The company will divest rights to Nexium in Europe and the global rights to Vimovo to Grünenthal

Original Article: AstraZeneca sells drug rights for $815 million

NEXT ARTICLE

More From BioPortfolio on "AstraZeneca sells drug rights for $815 million"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...